Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2017

01-09-2017

Targeting metabolic pathways for head and neck cancers therapeutics

Authors: Masashi Yamamoto, Hidenori Inohara, Takashi Nakagawa

Published in: Cancer and Metastasis Reviews | Issue 3/2017

Login to get access

Abstract

Cancer cells have distinctive energy metabolism pathways that support their rapid cell division. The preference for anaerobic glycolysis under the normal oxygen condition is known as the Warburg effect and has been observed in head and neck cancers. These metabolic changes are controlled by cancer-related transcription factors, such as tumor suppressor gene and hypoxia inducible factor 1α. In addition, various metabolic enzymes also actively regulate cancer-specific metabolism including the switch between aerobic and anaerobic glycolysis. For a long time, these metabolic changes in cancer cells have been considered a consequence of transformation required to maintain the high rate of tumor cell replication. However, recent studies indicate that alteration of metabolism is sufficient to initiate tumor transformation. Indeed, oncogenic mutations in the metabolic enzymes, isocitrate dehydrogenase and succinate dehydrogenase, have been increasingly found in various cancers, including head and neck cancers. In the present review, we introduce recent findings regarding the cancer metabolism, including the molecular mechanisms of how they affect cancer pathogenesis and maintenance. We also discuss the current and future perspectives on therapeutics that target metabolic pathways, with an emphasis on head and neck cancer.
Literature
1.
2.
Warburg, O., Posener, K., & Negelein, E. (1924). Ueber den stoffwechsel der tumoren. Biochemische Zeitschrift, 152, 319–344.
3.
4.
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011). Regulation of cancer cell metabolism. Nature Reviews. Cancer, 11(2), 85–95.CrossRefPubMed
5.
6.
Schoder, H., Fury, M., Lee, N., & Kraus, D. (2009). PET monitoring of therapy response in head and neck squamous cell carcinoma. Journal of Nuclear Medicine, 50(Suppl 1), 74S–88S.CrossRefPubMed
7.
Cammaroto, G., Quartuccio, N., Sindoni, A., Di Mauro, F., Caobelli, F., & Young, A. W. G. (2016). The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature. European Archives of Oto-Rhino-Laryngology, 273(8), 1961–1973.CrossRefPubMed
8.
Hanamoto, A., Tatsumi, M., Takenaka, Y., Hamasaki, T., Yasui, T., Nakahara, S., et al. (2014). Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapy. Cancer Medicine, 3(5), 1368–1376.CrossRefPubMedPubMedCentral
9.
Gross, A. M., Orosco, R. K., Shen, J. P., Egloff, A. M., Carter, H., Hofree, M., et al. (2014). Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics, 46(9), 939–943.CrossRefPubMedPubMedCentral
10.
11.
Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004). The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Research, 64(7), 2627–2633.CrossRefPubMed
12.
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126(1), 107–120.CrossRefPubMed
13.
Jiang, P., Du, W., Wang, X., Mancuso, A., Gao, X., Wu, M., et al. (2011). p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nature Cell Biology, 13(3), 310–316.CrossRefPubMedPubMedCentral
14.
Matoba, S., Kang, J. G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., et al. (2006). p53 regulates mitochondrial respiration. Science, 312(5780), 1650–1653.CrossRefPubMed
15.
Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A., & Feng, Z. (2010). Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proceedings of the National Academy of Sciences of the United States of America, 107(16), 7455–7460.CrossRefPubMedPubMedCentral
16.
Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., et al. (2007). The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Research, 67(7), 3043–3053.CrossRefPubMed
17.
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T. Y., Huang, L. E., et al. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biology, 2(7), 423–427.CrossRefPubMed
18.
Brahimi-Horn, M. C., Chiche, J., & Pouyssegur, J. (2007). Hypoxia signalling controls metabolic demand. Current Opinion in Cell Biology, 19(2), 223–229.CrossRefPubMed
19.
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism, 3(3), 187–197.CrossRefPubMed
20.
Lu, H., Forbes, R. A., & Verma, A. (2002). Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. The Journal of Biological Chemistry, 277(26), 23111–23115.CrossRefPubMed
21.
Semenza, G. L., Jiang, B. H., Leung, S. W., Passantino, R., Concordet, J. P., Maire, P., et al. (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. The Journal of Biological Chemistry, 271(51), 32529–32537.CrossRefPubMed
22.
Ullah, M. S., Davies, A. J., & Halestrap, A. P. (2006). The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. The Journal of Biological Chemistry, 281(14), 9030–9037.CrossRefPubMed
23.
Semenza, G. L. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 29(5), 625–634.CrossRefPubMed
24.
Beasley, N. J., Leek, R., Alam, M., Turley, H., Cox, G. J., Gatter, K., et al. (2002). Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Research, 62(9), 2493–2497.PubMed
25.
Gong, L., Zhang, W., Zhou, J., Lu, J., Xiong, H., Shi, X., et al. (2013). Prognostic value of HIFs expression in head and neck cancer: a systematic review. PloS One, 8(9), e75094.CrossRefPubMedPubMedCentral
26.
Mathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2006). Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene, 25(34), 4777–4786.CrossRefPubMedPubMedCentral
27.
Nakashima, R. A., Mangan, P. S., Colombini, M., & Pedersen, P. L. (1986). Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N′-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry, 25(5), 1015–1021.CrossRefPubMed
28.
Shinohara, Y., Sagawa, I., Ichihara, J., Yamamoto, K., Terao, K., & Terada, H. (1997). Source of ATP for hexokinase-catalyzed glucose phosphorylation in tumor cells: dependence on the rate of oxidative phosphorylation relative to that of extramitochondrial ATP generation. Biochimica et Biophysica Acta, 1319(2–3), 319–330.CrossRefPubMed
29.
Baschnagel, A. M., Wobb, J. L., Di lworth, J. T., Williams, L., Eskandari, M., Wu, D., et al. (2015). The association of (18)F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas. Radiotherapy and Oncology, 117(1), 118–124.CrossRefPubMed
30.
Peschiaroli, A., Giacobbe, A., Formosa, A., Markert, E. K., Bongiorno-Borbone, L., Levine, A. J., et al. (2013). miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene, 32(6), 797–802.CrossRefPubMed
31.
Pelicano, H., Martin, D. S., Xu, R. H., & Huang, P. (2006). Glycolysis inhibition for anticancer treatment. Oncogene, 25(34), 4633–4646.CrossRefPubMed
32.
Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., et al. (2004). 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Research, 64(1), 31–34.CrossRefPubMed
33.
Geschwind, J. F., Ko, Y. H., Torbenson, M. S., Magee, C., & Pedersen, P. L. (2002). Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Research, 62(14), 3909–3913.PubMed
34.
Ko, Y. H., Smith, B. L., Wang, Y., Pomper, M. G., Rini, D. A., Torbenson, M. S., et al. (2004). Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochemical and Biophysical Research Communications, 324(1), 269–275.CrossRefPubMed
35.
Sandulache, V. C., Ow, T. J., Pickering, C. R., Frederick, M. J., Zhou, G., Fokt, I., et al. (2011). Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer, 117(13), 2926–2938.CrossRefPubMedPubMedCentral
36.
Nakajo, M., Kajiya, Y., Tani, A., Yoneda, S., Shirahama, H., Higashi, M., et al. (2012). 18FDG PET for grading malignancy in thymic epithelial tumors: significant differences in 18FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study. European Journal of Radiology, 81(1), 146–151.CrossRefPubMed
37.
Paudyal, B., Oriuchi, N., Paudyal, P., Higuchi, T., Nakajima, T., & Endo, K. (2008). Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Science, 99(2), 260–266.CrossRefPubMed
38.
Paudyal, B., Oriuchi, N., Paudyal, P., Tsushima, Y., Higuchi, T., Miyakubo, M., et al. (2008). Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Annals of Nuclear Medicine, 22(1), 83–86.CrossRefPubMed
39.
Tanaka, T., Harano, Y., Sue, F., & Morimura, H. (1967). Crystallization, characterization and metabolic regulation of two types of pyruvate kinase isolated from rat tissues. Journal of Biochemistry, 62(1), 71–91.CrossRefPubMed
40.
Noguchi, T., Yamada, K., Inoue, H., Matsuda, T., & Tanaka, T. (1987). The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. The Journal of Biological Chemistry, 262(29), 14366–14371.PubMed
41.
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., et al. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452(7184), 230–233.CrossRefPubMed
42.
Mazurek, S. (2011). Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. The International Journal of Biochemistry & Cell Biology, 43(7), 969–980.CrossRef
43.
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., et al. (2013). PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell, 155(2), 397–409.CrossRefPubMed
44.
David, C. J., Chen, M., Assanah, M., Canoll, P., & Manley, J. L. (2010). HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature, 463(7279), 364–368.CrossRefPubMed
45.
Wong, T. S., Liu, X. B., Chung-Wai Ho, A., Po-Wing Yuen, A., Wai-Man Ng, R., & Ignace Wei, W. (2008). Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. International Journal of Cancer, 123(2), 251–257.CrossRefPubMed
46.
McDonnell, S. R., Hwang, S. R., Rolland, D., Murga-Zamalloa, C., Basrur, V., Conlon, K. P., et al. (2013). Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. Blood, 122(6), 958–968.CrossRefPubMedPubMedCentral
47.
Tamada, M., Nagano, O., Tateyama, S., Ohmura, M., Yae, T., Ishimoto, T., et al. (2012). Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Research, 72(6), 1438–1448.CrossRefPubMed
48.
Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J. K., Shen, M., et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science, 334(6060), 1278–1283.CrossRefPubMedPubMedCentral
49.
Desai, S., Ding, M., Wang, B., Lu, Z., Zhao, Q., Shaw, K., et al. (2014). Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget, 5(18), 8202–8210.CrossRefPubMed
50.
Bluemlein, K., Gluckmann, M., Gruning, N. M., Feichtinger, R., Kruger, A., Wamelink, M., et al. (2012). Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis. Oncotarget, 3(11), 1356–1369.CrossRefPubMedPubMedCentral
51.
Wang, Y., Zhang, X., Zhang, Y., Zhu, Y., Yuan, C., Qi, B., et al. (2015). Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma. Cancer Biology & Therapy, 16(6), 839–845.CrossRef
52.
Feng, C., Gao, Y., Wang, C., Yu, X., Zhang, W., Guan, H., et al. (2013). Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism, 98(9), E1524–E1533.CrossRefPubMed
53.
54.
55.
Dang, L., Jin, S., & Su, S. M. (2010). IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine, 16(9), 387–397.CrossRefPubMed
56.
Yang, H., Ye, D., Guan, K. L., & Xiong, Y. (2012). IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clinical Cancer Research, 18(20), 5562–5571.CrossRefPubMedPubMedCentral
57.
Ye, D., Ma, S., Xiong, Y., & Guan, K. L. (2013). R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell, 23(3), 274–276.CrossRefPubMedPubMedCentral
58.
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., et al. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. The Journal of Experimental Medicine, 207(2), 339–344.CrossRefPubMedPubMedCentral
59.
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462(7274), 739–744.CrossRefPubMedPubMedCentral
60.
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17(3), 225–234.CrossRefPubMedPubMedCentral
61.
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell, 19(1), 17–30.CrossRefPubMedPubMedCentral
62.
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., et al. (2012). IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 483(7390), 474–478.CrossRefPubMedPubMedCentral
63.
Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., et al. (2009). Mutation in TET2 in myeloid cancers. The New England Journal of Medicine, 360(22), 2289–2301.CrossRefPubMed
64.
Colvin, H., Nishida, N., Konno, M., Haraguchi, N., Takahashi, H., Nishimura, J., et al. (2016). Oncometabolite D-2-Hydroxyglurate directly induces epithelial-mesenchymal transition and is associated with distant metastasis in colorectal cancer. Scientific Reports, 6, 36289.CrossRefPubMedPubMedCentral
65.
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., et al. (2012). Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 483(7390), 484–488.CrossRefPubMedPubMedCentral
66.
Masson, N., & Ratcliffe, P. J. (2014). Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab, 2(1), 3.CrossRefPubMedPubMedCentral
67.
Yankovskaya, V., Horsefield, R., Tornroth, S., Luna-Chavez, C., Miyoshi, H., Leger, C., et al. (2003). Architecture of succinate dehydrogenase and reactive oxygen species generation. Science, 299(5607), 700–704.CrossRefPubMed
68.
King, A., Selak, M. A., & Gottlieb, E. (2006). Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene, 25(34), 4675–4682.CrossRefPubMed
69.
Hao, H. X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J. P., Kunst, H., et al. (2009). SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 325(5944), 1139–1142.CrossRefPubMed
70.
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., et al. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287(5454), 848–851.CrossRefPubMed
71.
Bardella, C., Pollard, P. J., & Tomlinson, I. (2011). SDH mutations in cancer. Biochimica et Biophysica Acta, 1807(11), 1432–1443.CrossRefPubMed
72.
Kirmani, S., & Young, W. F. (1993). Hereditary paraganglioma-pheochromocytoma syndromes. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, et al. (Eds.), GeneReviews(R). Seattle (WA).
73.
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., et al. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7(1), 77–85.CrossRefPubMed
74.
Favier, J., & Gimenez-Roqueplo, A. P. (2010). Pheochromocytomas: the (pseudo)-hypoxia hypothesis. Best Practice & Research. Clinical Endocrinology & Metabolism, 24(6), 957–968.CrossRef
75.
Xiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H., et al. (2012). Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes & Development, 26(12), 1326–1338.CrossRef
76.
Chiarugi, A., Dolle, C., Felici, R., & Ziegler, M. (2012). The NAD metabolome—a key determinant of cancer cell biology. Nature Reviews. Cancer, 12(11), 741–752.CrossRefPubMed
77.
78.
79.
Revollo, J. R., Grimm, A. A., & Imai, S. (2004). The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. The Journal of Biological Chemistry, 279(49), 50754–50763.CrossRefPubMed
80.
Yamamoto, M., Hikosaka, K., Mahmood, A., Tobe, K., Shojaku, H., Inohara, H., et al. (2016). Nmnat3 is dispensable in mitochondrial NAD level maintenance in vivo. PloS One, 11(1), e0147037.CrossRefPubMedPubMedCentral
81.
Sampath, D., Zabka, T. S., Misner, D. L., O'Brien, T., & Dragovich, P. S. (2015). Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacology & Therapeutics, 151, 16–31.CrossRef
82.
Patel, S., Ansari, J., Meram, A., Abdulsattar, J., Cotelingam, J., Coppola, D., et al. (2017). Increased nicotinamide phosphoribosyltransferase and cystathionine-beta-synthase in oral cavity squamous cell carcinomas. International Journal of Clinical and Experimental Pathology, 10(1), 702–707.
83.
Tan, B., Young, D. A., Lu, Z. H., Wang, T., Meier, T. I., Shepard, R. L., et al. (2013). Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. The Journal of Biological Chemistry, 288(5), 3500–3511.CrossRefPubMed
84.
Hikosaka, K., Ikutani, M., Shito, M., Kazuma, K., Gulshan, M., Nagai, Y., et al. (2014). Deficiency of nicotinamide mononucleotide adenylyltransferase 3 (nmnat3) causes hemolytic anemia by altering the glycolytic flow in mature erythrocytes. The Journal of Biological Chemistry, 289(21), 14796–14811.CrossRefPubMedPubMedCentral
85.
Hasmann, M., & Schemainda, I. (2003). FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Research, 63(21), 7436–7442.PubMed
86.
Goldinger, S. M., Gobbi Bischof, S., Fink-Puches, R., Klemke, C. D., Dreno, B., Bagot, M., et al. (2016). Efficacy and safety of APO866 in patients with refractory or relapsed cutaneous T-cell lymphoma: a phase 2 clinical trial. JAMA Dermatology, 152(7), 837–839.CrossRefPubMed
87.
Gehrke, I., Bouchard, E. D., Beiggi, S., Poeppl, A. G., Johnston, J. B., Gibson, S. B., et al. (2014). On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. Clinical Cancer Research, 20(18), 4861–4872.CrossRefPubMed
88.
Chan, M., Gravel, M., Bramoulle, A., Bridon, G., Avizonis, D., Shore, G. C., et al. (2014). Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Research, 74(21), 5948–5954.CrossRefPubMed
89.
Kato, H., Ito, E., Shi, W., Alajez, N. M., Yue, S., Lee, C., et al. (2010). Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clinical Cancer Research, 16(3), 898–911.CrossRefPubMed
90.
Petrelli, R., Felczak, K., & Cappellacci, L. (2011). NMN/NaMN adenylyltransferase (NMNAT) and NAD kinase (NADK) inhibitors: chemistry and potential therapeutic applications. Current Medicinal Chemistry, 18(13), 1973–1992.CrossRefPubMed
91.
Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., et al. (2012). Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Molecular Medicine, 4(10), 1087–1096.CrossRefPubMedPubMedCentral
92.
Wurster, S., Hennes, F., Parplys, A. C., Seelbach, J. I., Mansour, W. Y., Zielinski, A., et al. (2016). PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response. Oncotarget, 7(9), 9732–9741.CrossRefPubMedPubMedCentral
93.
Chalkiadaki, A., & Guarente, L. (2015). The multifaceted functions of sirtuins in cancer. Nature Reviews. Cancer, 15(10), 608–624.CrossRefPubMed
94.
Menssen, A., Hydbring, P., Kapelle, K., Vervoorts, J., Diebold, J., Luscher, B., et al. (2012). The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proceedings of the National Academy of Sciences of the United States of America, 109(4), E187–E196.CrossRefPubMed
95.
Kikuchi, K., Noguchi, A., Kasajima, R., Miyagi, Y., Hoshino, D., Koshikawa, N., et al. (2015). Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma. Tumour Biology, 36(10), 7865–7872.CrossRefPubMed
96.
Lai, C. C., Lin, P. M., Lin, S. F., Hsu, C. H., Lin, H. C., Hu, M. L., et al. (2013). Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biology, 34(3), 1847–1854.CrossRefPubMed
97.
Lu, C. T., Hsu, C. M., Lin, P. M., Lai, C. C., Lin, H. C., Yang, C. H., et al. (2014). The potential of SIRT6 and SIRT7 as circulating markers for head and neck squamous cell carcinoma. Anticancer Research, 34(12), 7137–7143.PubMed
Metadata
Title
Targeting metabolic pathways for head and neck cancers therapeutics
Authors
Masashi Yamamoto
Hidenori Inohara
Takashi Nakagawa
Publication date
01-09-2017
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9691-z

Other articles of this Issue 3/2017

Cancer and Metastasis Reviews 3/2017 Go to the issue

OriginalPaper

Preface

OriginalPaper

Alcohol and head and neck cancer

OriginalPaper

Tobacco-related carcinogenesis in head and neck cancer

OriginalPaper

Checkpoint immunotherapy in head and neck cancers

OriginalPaper

Tumor DNA: an emerging biomarker in head and neck cancer

OriginalPaper

The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits